ResearcherUniversité Paris CitéNo recent work listed

Flore Pignon

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5082647686. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2021: 1 paper

Papers 1

Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.05.006 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Vinciane Rebours · 1 shared paper, 2021 · strength 0.12
- Paper Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.05.006 ↗
Anthony Turpin · 1 shared paper, 2021 · strength 0.12
- Paper Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.05.006 ↗
Olivia Hentic Dhome · 1 shared paper, 2021 · strength 0.12
- Paper Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.05.006 ↗
Louis de Mestier · 1 shared paper, 2021 · strength 0.12
- Paper Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.05.006 ↗
Pascal R. Hammel · 1 shared paper, 2021 · strength 0.12
- Paper Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.05.006 ↗
Romain Coriat · 1 shared paper, 2021 · strength 0.12
- Paper Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.05.006 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.